Literature DB >> 12003006

Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus.

Kazuo Hatano1, Yoshihiko Morishita, Toru Nakai, Fumiaki Ikeda.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12003006     DOI： 10.7164/antibiotics.55.219

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN： 0021-8820            Impact factor:   2.649


× No keyword cloud information.
  13 in total

1.  Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults.

Authors:  J Keirns; T Sawamoto; M Holum; D Buell; W Wisemandle; A Alak
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

2.  Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients.

Authors:  Nita L Seibel; Cindy Schwartz; Antonio Arrieta; Patricia Flynn; Aziza Shad; Edith Albano; James Keirns; Wendi M Lau; David P Facklam; Donald N Buell; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant.

Authors:  J Hiemenz; P Cagnoni; D Simpson; S Devine; N Chao; J Keirns; W Lau; D Facklam; D Buell
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

4.  Effect of blood decrease on micafungin disposition in rats.

Authors:  Hiroki Konishi; Keizo Fukushima; Masatomo Sudo; Masaki Sumi; Tokuzo Minouchi; Ikumi Iga; Nobuhito Shibata; Akira Yamaji
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-02-25       Impact factor: 2.441

5.  In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds.

Authors:  Mamiko Miyazaki; Takaaki Horii; Katsura Hata; Nao-Aki Watanabe; Kazutaka Nakamoto; Keigo Tanaka; Syuji Shirotori; Norio Murai; Satoshi Inoue; Masayuki Matsukura; Shinya Abe; Kentaro Yoshimatsu; Makoto Asada
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

Review 6.  Advances in the treatment of invasive neonatal candidiasis.

Authors:  Lorena Botero-Calderon; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  Expert Opin Pharmacother       Date:  2015-04-05       Impact factor: 4.103

7.  Safety and pharmacokinetics of repeat-dose micafungin in young infants.

Authors:  D K Benjamin; P B Smith; A Arrieta; L Castro; P J Sánchez; D Kaufman; L J Arnold; L L Kovanda; T Sawamoto; D N Buell; W W Hope; T J Walsh
Journal:  Clin Pharmacol Ther       Date:  2009-11-04       Impact factor: 6.875

8.  Killing activity of micafungin against Aspergillus fumigatus hyphae assessed by specific fluorescent staining for cell viability.

Authors:  Etsuko Watabe; Toru Nakai; Satoru Matsumoto; Fumiaki Ikeda; Kazuo Hatano
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

9.  Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation.

Authors:  Yasushi Hiramatsu; Yoshinobu Maeda; Nobuharu Fujii; Takashi Saito; Yuichiro Nawa; Masamichi Hara; Tomofumi Yano; Shoji Asakura; Kazutaka Sunami; Takayuki Tabayashi; Akira Miyata; Ken-Ichi Matsuoka; Katsuji Shinagawa; Kazuma Ikeda; Keitaro Matsuo; Mitsune Tanimoto
Journal:  Int J Hematol       Date:  2008-11-29       Impact factor: 2.490

Review 10.  The use of antifungal therapy in neonatal intensive care.

Authors:  Daniela Testoni; P Brian Smith; Daniel K Benjamin
Journal:  Clin Perinatol       Date:  2012-01-11       Impact factor: 2.642
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.